Grimes & Company, Inc. Vertex Pharmaceuticals Inc Transaction History
Grimes & Company, Inc.
- $3.18 Billion
- Q1 2025
A detailed history of Grimes & Company, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Grimes & Company, Inc. holds 706 shares of VRTX stock, worth $353,134. This represents 0.01% of its overall portfolio holdings.
Number of Shares
706
Previous 649
8.78%
Holding current value
$353,134
Previous $261,000
31.03%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding VRTX
# of Institutions
1,807Shares Held
224MCall Options Held
1.62MPut Options Held
1.46M-
Capital World Investors Los Angeles, CA28.3MShares$14.2 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$11.6 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.7 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.99 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$5.22 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $128B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...